The ORA-based screening of the WGCNA modules was performed to capture clinically important modules and their upstream regulators, which reflect the disease mechanisms affected differentially under the different driver EGFR mutations in lung adenocarcinoma. This evidence concerns the gene EGFR and lung adenocarcinoma.